Literature DB >> 8890999

A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.

A Matsuno1, T Sasaki, T Mochizuki, T Fujimaki, N Sanno, Y Osamura, A Teramoto, T Kirino.   

Abstract

Somatotroph adenomas often secrete prolactin (PRL) besides growth hormone (GH) and are sometimes immunostained for other anterior pituitary hormones or their subunits, such as thyroid-stimulating hormone (TSH) beta-subunit and glycoprotein hormone alpha-subunit (alpha SU). However, somatotroph adenomas showing hypersecretion of adrenocorticotropic hormone (ACTH) are extremely rare. There have been, to our knowledge, only five published reports on somatotroph adenomas accompanied by excessive ACTH secretion. Here we report a case of intracavernously invading somatotroph macro-adenoma with high serum GH, PRL, and ACTH levels. We examined the case using immunohistochemistry (IHC), in situ hybridization (ISH), and cell culture, and confirmed GH, PRL, and ACTH, as well as alpha SU, production, and the expression of Pit-1 protein by the adenoma, which is known as a transcriptional factor for GH, PRL, and TSH, not for ACTH. Therefore, the presence of unknown transcriptional factor other than Pit-1, common to GH, PRL, and ACTH, may be speculated to be expressed in this adenoma. In our previous study, we had found plurihormonal mRNA expression, especially for ACTH, the beta-subunit of follicle-stimulating hormone and luteinizing hormone in some somatotroph adenomas, using non-radio-isotopic ISH, and suggested that these adenomas might be derived from plurihormonal primordial stem cells. Our present case is significant from the viewpoint of histogenesis of pituitary adenomas, because it further supports the cell origin of somatotroph adenomas from plurihormonal primordial stem cells, and moreover it suggests the presence of unknown transcriptional factor other than Pit-1, common to GH, PRL, and ACTH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890999     DOI: 10.1007/bf01411291

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  23 in total

1.  Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis.

Authors:  H M Schulte; E H Oldfield; B Allolio; D A Katz; R A Berkman; I U Ali
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

2.  Effects of estradiol on prolactin and growth hormone messenger RNAs in cultured normal and neoplastic (MtT/W15 and GH3) rat pituitary cells.

Authors:  J Y Song; L Jin; R V Lloyd
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

3.  Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.

Authors:  R V Lloyd; M Cano; W F Chandler; A L Barkan; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

4.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  Application of biotinylated oligonucleotide probes to the detection of pituitary hormone mRNA using northern blot analysis, in situ hybridization at the light- and electron-microscope levels.

Authors:  A Matsuno; A Teramoto; S Takekoshi; H Utsunomiya; Y Ohsugi; S Kishikawa; R Y Osamura; T Kirino; R V Lloyd
Journal:  Histochem J       Date:  1994-10

6.  GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.

Authors:  N Sanno; A Teramoto; A Matsuno; S Takekoshi; R Y Osamura
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

7.  Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.

Authors:  J Li; L Stefaneanu; K Kovacs; E Horvath; H S Smyth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Analysis of pituitary hormones and chromogranin A mRNAs in null cell adenomas, oncocytomas, and gonadotroph adenomas by in situ hybridization.

Authors:  R V Lloyd; L Jin; K Fields; W F Chandler; E Horvath; L Stefaneanu; K Kovacs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

9.  Multihormonal response to CRH in a patient with Cushing syndrome and a pituitary adenoma producing ACTH and GH.

Authors:  M J Bugalho; J F Nunes; L G Sobrinho; E Medina; J A Campos; C G da Silva; A L Clode
Journal:  Acta Endocrinol (Copenh)       Date:  1993-03

10.  Clonal origin of pituitary adenomas.

Authors:  V Herman; J Fagin; R Gonsky; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

View more
  4 in total

1.  From macroprolactinoma to concomitant ACTH-PRL hypersecretion with Cushing's disease.

Authors:  M Barausse; R Attanasio; D Dallabonzana; G Oppizzi; S Veronese; G Lasio; L G Valentini; R Cozzi
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

2.  Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma.

Authors:  Rajesh Rajendran; Sarita Naik; Derek D Sandeman; Azraai B Nasruddin
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2013-08-30

3.  Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma.

Authors:  Ruoyu Shi; Xueyan Wan; Zisheng Yan; Zhoubin Tan; Xiaojin Liu; Ting Lei
Journal:  Front Surg       Date:  2022-02-25

4.  A GRFa2/Prop1/stem (GPS) cell niche in the pituitary.

Authors:  Montse Garcia-Lavandeira; Víctor Quereda; Ignacio Flores; Carmen Saez; Esther Diaz-Rodriguez; Miguel A Japon; Aymee K Ryan; Maria A Blasco; Carlos Dieguez; Marcos Malumbres; Clara V Alvarez
Journal:  PLoS One       Date:  2009-03-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.